Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Bolt Biotherapeutics Q2 EPS $(4.46) Beats $(6.27) Estimate, Sales $1.80M Beat $819.75K Estimate

Author: Benzinga Newsdesk | August 14, 2025 04:41pm
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.46) per share which beat the analyst consensus estimate of $(6.27) by 28.83 percent. This is a 60.18 percent increase over losses of $(11.20) per share from the same period last year. The company reported quarterly sales of $1.80 million which beat the analyst consensus estimate of $819.75 thousand by 120.07 percent. This is a 41.49 percent increase over sales of $1.27 million the same period last year.

Posted In: BOLT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist